Mrinal Gounder, MD
Sarcoma Medical Oncology and Early Drug Development
(Phase 1) Services
Memorial Sloan Kettering Cancer Center
New York, NY
Jonathan Trent, MD, PhD
Professor of Medicine
Director, Sarcoma Medical Research Program
Sylvester Comprehensive Cancer Center
University of Miami
This case-based activity will cover the pathology, genetic characteristics, and therapeutic management options for patients with epithelioid sarcoma (ES).
This activity is designed to meet the educational needs of US-based hematologists, oncologists, pathologists, and surgeons involved in the diagnosis and therapeutic management of patients with ES.
- Describe the pathology and clinical presentation of ES, the process of differential diagnosis, and the importance of consultation with surgical oncologists
- Discuss the molecular/genetic characteristics of ES including the roles of INI1 gene aberrations and the EZH2 protein that can inform potential therapeutic targets
- Review the MOAs and clinical profiles of recently approved and emerging medicinal treatment options for patients with locally advanced or metastatic ES
- Plan patient management strategies that include novel medicinal treatment options for locally advanced or metastatic ES where appropriate
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 1.25 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the therapeutic management of patients with epithelioid sarcoma.
CNE Credits: 1.25 ANCC Contact Hour(s).
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Mrinal Gounder, MD has received consulting fees from Epizyme.
Jonathan Trent, MD, PhD has received clinical research funding by and advised Blueprint Medicines, Deciphera Pharmaceuticals, C4 therapeutics.
CME Content Review
CNE Content Review
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Marcello Morgan, MD, MPH, Medical Director of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
RELEASE DATE: November 30, 2020
EXPIRATION DATE: November 30, 2021
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at email@example.com.
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.